Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
WikiMesothelioma — Mesothelioma Knowledge Base
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Survival Statistics
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== What Emerging Biomarkers Predict Survival? == Advanced biomarker testing is transforming mesothelioma prognosis from population-based statistics to individualized predictions.<ref>[https://mesothelioma.net/mesothelioma-diagnosis/ Mesothelioma Diagnosis], Mesothelioma.net</ref> '''Liquid Biopsy (ctDNA):''' A landmark 2025 Nature Medicine study validated circulating tumor DNA monitoring as a powerful prognostic tool.<ref>[https://dandell.com/mesothelioma/mesothelioma-diagnosis/mesothelioma-cancer-guide/ Mesothelioma Cancer Guide], Danziger & De Llano</ref> Patients achieving undetectable ctDNA at cycle 3 day 1 demonstrated median progression-free survival of 19.84 months versus just 1.41 months for those with detectable ctDNA. Those achieving ≥95% ctDNA reduction showed median PFS of 23.26 months versus 1.68 months—a more than 13-fold difference. '''BAP1 Mutation Status:''' Present in over 50% of mesotheliomas, BAP1 mutation paradoxically predicts better survival (median 5 years versus less than 1 year without mutation) while also indicating potential sensitivity to targeted therapies like tazemetostat.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma-cancer/diagnosis/ Mesothelioma Diagnosis], Mesothelioma Lawyer Center</ref> '''Ki-67 Proliferation Index:''' For peritoneal mesothelioma, Ki-67 ≤9% predicts median survival of 86.6 months versus 10.3 months for Ki-67 >9%—an 8-fold difference.<ref>[https://mesothelioma.net/mesothelioma-facts/ Mesothelioma Information], Mesothelioma.net</ref> '''Methylation-Based Classification:''' cfMeDIP-seq liquid biopsy can distinguish epithelioid from sarcomatoid histology with 98% accuracy and identify prognostic methylation signatures non-invasively.<ref>[https://mesotheliomaattorney.com/mesothelioma/cancer/ Mesothelioma Cancer Explained], Mesothelioma Attorney</ref> {| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;" |- | style="padding:15px; color:#856404;" | '''⚠ Important Legal Consideration''' Improved survival through newer treatments can extend the time available for pursuing legal compensation, but statutes of limitations still apply. Consulting with experienced mesothelioma attorneys early ensures families preserve all legal options. |}
Summary:
Please note that all contributions to WikiMesothelioma — Mesothelioma Knowledge Base may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
WikiMesothelioma:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Survival Statistics
(section)
Add topic